Nucleic Acids Research, 2002, Vol. 30, No. 7 1493-1499
© 2002 Oxford University Press
Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase
-primase
Institut für Molekulare Biotechnologie e.V., Abteilung Biochemie, Beutenbergstrasse 11, D-07745 Jena, Germany
The wild-type form of p53 contains an intrinsic 3'5'-exonuclease activity. As p53 forms a complex with DNA polymerase
-primase (pol-prim) in vivo this finding suggests that p53 might cooperate with pol-prim to stabilize the genetic information of living cells. To test this hypothesis, exonuclease-free DNA pol-prim was expressed alone or together with p53 for purification. Pol-prim formed a complex with p53, which was purified by ion exchange and immunoaffinity chromatography from baculovirus-infected insect cells. The p53-containing pol-prim fractions removed a 3'-unpaired nucleotide with a 1.52-fold higher rate than a paired nucleotide, whereas the four subunit pol-prim did not have any exonuclase activity. Therefore, only p53/pol-prim was able to elongate a primer-template that contained a 3'-unpaired primer end in vitro. To achieve this, the 3'5'-exonuclease activity of p53 excised the unpaired nucleotide at the 3'-end of the primer and created a paired 3'-end, which pol-prim was able to elongate. The exonuclease activity of p53 as well as the elongation of a primer with a mispaired 3'-end was inhibited specifically by the anti-p53 monoclonal antibodies PAb240 and PAb421.
* To whom correspondence should be addressed. Tel: +49 3641 656290; Fax: +49 3641 656288; Email: nasheuer{at}imb-jena.de Present address:Christian Melle, Institut für Humangenetik und Anthropologie, Friedrich-Schiller-Universität, Kollegiengasse 10, D-07740 Jena, Germany
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Bakhanashvili, E. Novitsky, E. Rubinstein, I. Levy, and G. Rahav Excision of Nucleoside Analogs from DNA by p53 Protein, a Potential Cellular Mechanism of Resistance to Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1576 - 1579. [Abstract] [Full Text] [PDF] |
||||
